Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Completed

• Conditions: Prostate Cancer; Osteoporosis

• Registration Number: NCT01025479
• Lead Sponsor: AstraZeneca

Brief Summary

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11
• Study First Submitted: 2009-12-01
• Study First Submitted QC: 2009-12-02
• Study First Posted: 2009-12-03
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Status Verified: 2010-06
• Last Update Submitted: 2010-06-28
• Last Update Posted: 2010-06-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 829

Inclusion Criteria

• pathologic confirmation of prostate cancer
• patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria

• patients who are hard to be analysed by limitation of chart record according to investigators'discretion
• patients who already have been registered in this study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.

Secondary Outcome Measures

Name	Time	Method
To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.

Trial Locations

Locations (1)

Research Site; 🇰🇷 Ulsan, Korea, Republic of